Cryoablation of an atrioventricular nodal reentrant tachycardia in a patient with an implanted deep brain stimulator  by Gunawardene, Melanie et al.
Cryoablation of an atrioventricular nodal reentrant
tachycardia in a patient with an implanted deep brain
stimulator
Melanie Gunawardene, MD, Christian Meyer (Professor, MD) Stephan Willems (Professor, MD)
Boris Alexander Hoffmann, MD
From the University Heart Center Hamburg, Hamburg, Germany.Introduction
Atrioventricular nodal reentrant tachycardia (AVNRT) is the
most frequent paroxysmal supraventricular tachycardia
(SVT), with an incidence of 5 cases per 1000 people.
Ablation utilizing a radiofrequency current (RFC) energy
source is currently the standard treatment. Success rates range
between 94% and 100% and complication rates are low,
especially with respect to total atrioventricular (AV) block.1,2
Implantation of bilateral deep brain stimulators (DBS) is
an established treatment for severe, pharmacotherapy-
refractive Parkinson disease (PD).3,4 Acceptance of this
therapy has increased over the past ﬁfteen years, leading to
higher implantation rates; therefore, the incidence of patients
with DBS has increased.3
So far, one case report, published by Kanagaratnam et al,5
demonstrated the performance of a safe and successful RFC
ablation in a patient with DBS suffering from AVNRT
without device or patient complications.
However, the use of an RFC energy source in patients
treated with DBS can be dangerous. The electrodes and
generators used are generally known to have several
interactions, including those with radiofrequency (RF)
energy.6 Nutt et al6 reported a disastrous outcome of a
patient with implanted DBS who was treated by a form of RF
energy after an oral surgery, leading to severe brain injury.
Furthermore, DBS can cause signiﬁcant artifacts in
electrocardiographic recordings.7 As a result, catheter abla-
tion of cardiac arrhythmias in patients with PD and implanted
stimulators can be challenging, speciﬁcally as RFC is the
standard energy source used to create ablation lesions.
However, catheter ablation of SVT utilizing cryoenergy
has become an alternative to RFC ablations.1,8KEYWORDS Cryoablation; Supraventricular tachycardia; Atrioventricular
nodal reentrant tachycardia; Deep brain stimulation; Ablation; Parkinson
disease (Heart Rhythm Case Reports 2016;2:258–260)
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catheter ablation with cryoenergy in patients undergoing
DBS.Case report
A 66-year-old man suffering from PD treated with DBS was
admitted to our outpatient clinic with palpitations from
symptomatic SVT.
The patient had been suffering from PD for 5 years.
Owing to progressing tremor and rigidity, a DBS was
implanted in September 2013 (Activa PC; Medtronic Inc,
Minneapolis, MN). While he was still undergoing treatment
with levodopa, carbidopa, ropinirole, and entacapone, his
neurologic symptoms had nearly disappeared and subjec-
tively his quality of life had improved.
However, over the last ﬁve years he had also been
suffering from intermittent paroxysmal tachycardia with a
duration of 2–4 hours, typical “on-off” phenomenon, and
palpitations. Termination of the tachycardia in the past had
been achieved either with administration of adenosine or by
vagal maneuvers. Medication with metoprolol had reduced
the frequency of tachycardia; however, he still suffered from
highly symptomatic episodes.
A typical electrophysiological (EP) study with the use of
RF energy, however, did not seem feasible in a DBS patient.
We consulted with our neurosurgery department and the
DBS system engineers; they stated that interactions with the
DBS system, leading to heat generation and possibly severe
central nervous system damage, even in an off-state stim-
ulator, could not be excluded.
We therefore performed an EP study using cryoenergy
(Figure 1) (Arctic Frezzor®MAX; Medtronic Inc, Minneap-
olis, MN). Before we commenced the EP study, the DBS
device was ﬁrst interrogated. The electrocardiogram (ECG)
showed no artifacts with a stimulator frequency output of
125 Hz. Atrial and ventricular stimulations were performed
according to standard protocols. During ventricular pacing a
retrograde jump was detected (drive chain 370 ms, jump of
60 ms from S2 ¼ 300 ms to S2 ¼ 290 ms). The clinicalpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Cryoablation of atrioventricular nodal reentrant
tachycardia by slow pathway modulation in
patients with implanted deep brain stimulator
(DBS) seems safe and feasible. It does not cause
interactions with DBS systems.
 Tachyarrhythmias are frequent and increase in
aging patients. Thus, the use of cryoenergy instead
of radiofrequency current energy in patients with
DBS represents a safe and reasonable alternative.
 In the future, cryoenergy is not only a possibility to
treat atrioventricular nodal–dependent
tachyarrhythmias, but could also be used to
perform pulmonary vein isolation with the
cryoballoon in DBS patients suffering from atrial
ﬁbrillation.
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typical AVNRT (Figure 2).
After the required ablation criteria were determined, slow
pathway modulation was performed over two cryoenergy
freezes. The ﬁrst freeze started with a so-called “mapping
mode” at 301C to mark the ablation site without causing
durable AV node damage in case of misplacement, as
reported elsewhere.1 Over the course of the ﬁrst application
a minimal temperature of791C could be reached (Figure 3).
After a short warm-up phase the second freeze was applied,
reaching801C. Post ablation, the tachycardia was no longer
inducible and no retrograde jump was detected.
During the postprocedural in-patient stay at our clinic, no
complication occurred. Pericardial effusion was excluded by
echocardiography, there were no inguinal hematomas on
either side, no neurologic symptoms occurred, and post-
procedural interrogation of the DBS device showed no
dysfunction of the system. The patient was discharged the
next day in stable sinus rhythm. An 8-month follow-up of the
patient showed no recurrence.Figure 1 Fluoroscopic view of the ablation setting. Left: Positioning the cryo
different diagnostic catheters positioned at the high right atrium (HRA), right ventri
implanted in the left upper chest.Discussion
Implantation of DBS has become a common treatment for a
variety of neurologic diseases.9 Tachyarrhythmias are frequent
and increase in aging patients; for example, the prevalence of
atrial ﬁbrillation increases 5%–15% at 80 years.10 Thus, a safe
alternate ablation treatment for patients with implanted devices
needing catheter ablation of cardiac arrhythmias is required.
Severe central nervous system damage around the DBS
electrodes was reported in a patient after undergoing a form
of RF energy treatment to hasten recovery (pulse-modulated
RF diathermy) after oral surgery.6 In this speciﬁc case the
patient could not be aroused at the end of the RF energy
treatment. He had small pupils and had no response to pain.
A magnetic resonance imaging scan 3 days after the RF
energy treatment showed a severe, bilateral brain injury. One
month after his RF energy treatment the patient still could not
vocalize and needed percutaneous endoscopic gastrostomy.6
However, Kanagaratnam et al5 performed a successful
and uncomplicated RFC energy ablation in a patient with
DBS. They were able to reduce ECG artifacts by program-
ming the DBS from a unipolar to a bipolar mode, as well as
by reducing the system’s frequency output.5
In our patient no ECG artifacts appeared and adjustments to
the program settings were not necessary. Furthermore, Kanagar-
atnam et al5 report that RFC energy application did not interact
with the DBS and no central nervous system damage occurred.
However, this is the only case reported, and it does not solve the
underlying problem of technically possible interactions. Further,
the use of RFC catheters for ablation of cardiac arrhythmias is not
advised by the DBS manufacturer.
Cryoenergy is generated by refrigerant N2O undergoing a
liquid-to-gas phase change. This change results in cooling
down to approximately –801C. In general, the use of
cryoenergy for slow pathway modulation shows similar
acute success rates compared to RFC as the underlying
energy source (94%–97% vs 94%–100%). The general
complication rate, especially with respect to total AV block,
is low.1,2,11 Cryoablation, however, is limited by a slightly
lower long-term clinical efﬁcacy when compared to RFC
ablation (2%–19.8% cryoablation vs 1%–9% RFCcatheter at the location of the slow pathway in the Koch triangle with the
cle (RV), His bundle (His), and coronary sinus (CS). Right: Neurostimulator
Figure 2 Intracardiac electrogram showing the patient’s clinical tachycardia as a typical slow–fast atrioventricular nodal reentrant tachycardia (133 beats/min,
cycle length 450 ms). A ¼ atrial signal; H ¼ signal of the His bundle; V ¼ ventricular signal.
Heart Rhythm Case Reports, Vol 2, No 3, May 2016260recurrence rates).1 Overall, the use of cryoenergy instead of
RFC in patients with DBS represents a safe and reasonable
alternative. In the future, cryoenergy is not only a possibility
to treat AV nodal–dependent tachyarrhythmias, but it could
also be used to perform pulmonary vein isolation with the
cryoballoon in DBS patients suffering from atrial ﬁbrillation.Conclusion
Cryoablation of AVNRT by slow pathway modulation in
patients with implanted DBS seems safe and feasible, and
does not cause interactions with DBS systems.Figure 3 Temperature curve of the ﬁrst cryoablation application showing
the mapping mode at –301C (1) and the actual ablation with a minimum
temperature of –791C (2).References
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